SXTP
60 Degrees Pharmaceuticals Inc

2,037
Loading...
Loading...
News
all
press releases
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of +38.46% and +15.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Rating Reiterated by HC Wainwright
HC Wainwright reaffirmed their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP - Free Report) in a research report released on Wednesday morning, Benzinga reports. HC Wainwright...
Ticker Report·1y ago
News Placeholder
60 Degrees Pharmaceuticals to sponsor pilot study of tafenoquine
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
Study to be conducted by North Carolina State University in 2024Standard of care fails in 20 percent of cases and drug resistance is a problemStandard of care is expensive WASHINGTON, April 03...
Globe Newswire·1y ago
News Placeholder
Short Interest in 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Decreases By 56.9%
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP Get Free Report) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 65,500...
Ticker Report·1y ago
News Placeholder
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Stock Holdings Trimmed by Central Bank & Trust Co.
Central Bank & Trust Co. reduced its position in 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP Free Report) by 23.7% in the 4th quarter, according to the company in its most recent Form 13F...
Zolmax·1y ago
News Placeholder
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
WASHINGTON, March 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP, SXTPW) ( 60 Degrees Pharmaceuticals or the Company ), a pharmaceutical company focused on...
Globe Newswire·2y ago
News Placeholder
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitalsTafenoquine's presumed mode of action against C. auris is differentiated from standard of care...
Globe Newswire·2y ago
News Placeholder
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
To lead U.S. commercial relaunch of ARAKODA (tafenoquine) for malaria preventionWill support Company plan to expand clinical research strategy in tick-borne diseases beyond acute babesiosis...
Globe Newswire·2y ago
News Placeholder
WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering
WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering PR...
PR Newswire·2y ago

Latest SXTP News

View

Advertisement. Remove ads.

Advertisement. Remove ads.